Experimental CAR t therapy targets Hard-to-Treat AL amyloidosis

NCT ID NCT07250269

First seen Dec 08, 2025 · Last updated May 13, 2026 · Updated 21 times

Summary

This early-phase trial tests a new treatment called GC012F for people with AL amyloidosis that has come back or not responded to prior therapy. The therapy uses specially engineered immune cells to target two proteins on harmful cells. The study will enroll 9 adults to check safety and whether the treatment can reduce disease signs.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY AL AMYLOIDOSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Beijing, 100034, China

  • Research Site

    RECRUITING

    Beijing, 100070, China

  • Research Site

    RECRUITING

    Beijing, CN-100730, China

  • Research Site

    RECRUITING

    Changchun, 130021, China

  • Research Site

    RECRUITING

    Guangzhou, 510100, China

  • Research Site

    NOT_YET_RECRUITING

    Hangzhou, 310003, China

  • Research Site

    RECRUITING

    Suzhou, 215006, China

  • Research Site

    RECRUITING

    Wenzhou, 325000, China

  • Research Site

    NOT_YET_RECRUITING

    Wuhan, 430022, China

Conditions

Explore the condition pages connected to this study.